Zacks Research Has Negative Estimate for SRPT Q1 Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities research analysts at Zacks Research cut their Q1 2026 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued to clients and investors on Tuesday, April 8th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will earn $2.44 per share for the quarter, down from their prior estimate of $2.56. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.67 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q2 2026 earnings at $2.76 EPS, Q3 2026 earnings at $2.82 EPS, Q4 2026 earnings at $2.62 EPS, FY2026 earnings at $10.64 EPS and FY2027 earnings at $12.25 EPS.

Several other brokerages have also commented on SRPT. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price objective for the stock from $161.00 to $87.00 in a report on Monday, March 31st. Wells Fargo & Company initiated coverage on Sarepta Therapeutics in a report on Friday. They issued an “overweight” rating and a $115.00 target price on the stock. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. HC Wainwright raised Sarepta Therapeutics from a “sell” rating to a “neutral” rating and set a $75.00 price target on the stock in a report on Wednesday, April 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $161.83.

Sarepta Therapeutics Trading Up 1.4 %

NASDAQ SRPT opened at $51.03 on Thursday. The stock has a market cap of $4.95 billion, a P/E ratio of 40.82 and a beta of 0.93. The stock has a 50 day simple moving average of $88.11 and a two-hundred day simple moving average of $110.20. Sarepta Therapeutics has a fifty-two week low of $48.01 and a fifty-two week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Manchester Capital Management LLC increased its holdings in Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after buying an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB grew its holdings in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 156 shares during the period. Sunbelt Securities Inc. lifted its holdings in Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 232 shares during the period. Newbridge Financial Services Group Inc. purchased a new stake in Sarepta Therapeutics in the 4th quarter worth approximately $36,000. Finally, Steward Partners Investment Advisory LLC increased its holdings in shares of Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 194 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.